Spyre ( SYRE ) Q2 R&D Up 23% Loss Narrows
Spyre Therapeutics ( NASDAQ:SYRE ) , a clinical-stage biotechnology company focused on antibody therapies for inflammatory diseases, released its second quarter results on August 5, 2025. Notably, Q2 2025 earnings featured a one-time $10.0 million gain from the sale of legacy rights, but not ...
Spyre Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update - Spyre Therapeutics ( NASDAQ:SYRE )
Reported positive interim Phase 1 results for two next-generation TL1A antibodies, demonstrating both were well-tolerated, exhibited pharmacokinetic ( "PK" ) profiles supporting quarterly or biannual dosing, and full TL1A engagement through up to 20 weeks of follow-up
Spyre Therapeutics Announces Grants of Inducement Awards - Spyre Therapeutics ( NASDAQ:SYRE )
WALTHAM, Mass., July 03, 2025 ( GLOBE NEWSWIRE ) -- Spyre Therapeutics, Inc.
Wall Street Analysts Predict a 244.05% Upside in Spyre Therapeutics ( SYRE ) : Here's What You Should Know
The mean of analysts' price targets for Spyre Therapeutics (SYRE) points to a 244.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
How Much Upside is Left in Spyre Therapeutics ( SYRE ) ? Wall Street Analysts Think 258.34%
The average of price targets set by Wall Street analysts indicates a potential upside of 258.3% in Spyre Therapeutics (SYRE). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
This Weyerhaeuser Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Sun Communities ( NYSE:SUI ) , Ocular Therapeutix ( NASDAQ:OCUL )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Jefferies analyst Peter Abramowitz initiated coverage on Sun Communities, Inc.
Can Spyre Therapeutics ( SYRE ) Climb 158.85% to Reach the Level Wall Street Analysts Expect?
The consensus price target hints at a 158.9% upside potential for Spyre Therapeutics (SYRE). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
SPYRE ALERT: Bragar Eagel & Squire, P.C. is Investigating Spyre Therapeutics, Inc. on Behalf of Spyre Stockholders and Encourages Investors to Contact the Firm - Spyre Therapeutics ( NASDAQ:SYRE )
NEW YORK, Dec. 03, 2024 ( GLOBE NEWSWIRE ) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Spyre Therapeutics, Inc. ( "Spyre" or the "Company" ) SYRE on behalf of Spyre stockholders.
ARCA biopharma and Oruka Therapeutics Announce Merger Agreement
Merger to create a company focused on advancing Oruka's portfolio of novel biologics that aim to redefine the standard of care for patients with chronic skin diseases ...
ARCA biopharma and Oruka Therapeutics Announce Merger Agreement - ARCA biopharma ( NASDAQ:ABIO )
Merger to create a company focused on advancing Oruka's portfolio of novel biologics that aim to redefine the standard of care for patients with chronic skin diseases
ARCA biopharma and Oruka Therapeutics Announce Merger Agreement - ARCA biopharma ( NASDAQ:ABIO )
Merger to create a company focused on advancing Oruka's portfolio of novel biologics that aim to redefine the standard of care for patients with chronic skin diseases
Spyre Therapeutics Announces $180 Million Private Placement
WALTHAM, Mass., March 18, 2024 /PRNewswire/ -- Spyre Therapeutics, Inc. ( "Spyre" or the "Company" ) ( NASDAQ: SYRE ) , a biotechnology company advancing a pipeline of investigational antibody therapeutics with the potential to transform the treatment of inflammatory bowel disease ( "IBD" ) , ...
NIO Reports Upbeat Earnings, Joins Dave, V2X, Riskified And Other Big Stocks Moving Higher On Tuesday - Dave ( NASDAQ:DAVE ) , NIO ( NYSE:NIO ) , Riskified ( NYSE:RSKD )
U.S. stocks were lower, with the Dow Jones index falling more than 200 points on Tuesday. Shares of NIO Inc. NIO rose during Tuesday's session following upbeat quarterly results. NIO reported fourth-quarter revenue of 17.10 billion yuan ( $2.41 billion ) , up by 6.5% year-over-year and down by ...
Here's What Could Help Spyre Therapeutics ( SYRE ) Maintain Its Recent Price Strength
Spyre Therapeutics (SYRE) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Spyre Therapeutics Announces Grants of Inducement Awards
WALTHAM, Mass., March 1, 2024 /PRNewswire/ -- Spyre Therapeutics, Inc. ( NASDAQ: SYRE ) ( the "Company" or "Spyre" ) , a development-stage biotechnology company advancing best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches for the treatment of ...
Here's Why Spyre Therapeutics ( SYRE ) Could be Great Choice for a Bottom Fisher
After losing some value lately, a hammer chart pattern has been formed for Spyre Therapeutics (SYRE), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Spyre Therapeutics Appoints Accomplished Biopharma and IBD Leader Mark C. McKenna, Former Chairman ... - PR Newswire
Spyre Therapeutics Appoints Accomplished Biopharma and IBD Leader Mark C. McKenna, Former Chairman ... PR ...
Aeglea BioTherapeutics ( NASDAQ:AGLE ) Now Covered by Analysts at StockNews.com
StockNews.com assumed coverage on shares of Aeglea BioTherapeutics ( NASDAQ:AGLE - Free Report ) in a research note released on Saturday. The firm issued a sell rating on the biotechnology company's stock. The company has a market capitalization of $48.64 million, a PE ratio of -0.16 and a beta ...
Aeglea BioTherapeutics ( NASDAQ:AGLE ) Receives New Coverage from Analysts at StockNews.com
Research analysts at StockNews.com started coverage on shares of Aeglea BioTherapeutics ( NASDAQ:AGLE - Get Free Report ) in a note issued to investors on Friday. The firm set a "sell" rating on the biotechnology company's stock. Aeglea BioTherapeutics has a twelve month low of $2.66 and a ...
Spyre Therapeutics Announces $180 Million Private Placement
WALTHAM, Mass., Dec. 7, 2023 /PRNewswire/ -- Spyre Therapeutics, Inc. ( "Spyre" ) ( NASDAQ: SYRE ) , a biotechnology company advancing a pipeline of antibody therapeutics with the potential to transform the treatment of inflammatory bowel disease ( "IBD" ) , today announced that it has entered ...
Aeglea BioTherapeutics ( NASDAQ:AGLE ) Earns Sell Rating from Analysts at StockNews.com
StockNews.com started coverage on shares of Aeglea BioTherapeutics ( NASDAQ:AGLE - Get Free Report ) in a research report issued on Thursday. The firm set a "sell" rating on the biotechnology company's stock.
